Clinical Trials

An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)

Study ID
Bristol-Myers Squibb CA209-568

NCT Number
NCT02659059 (Click on the NCT number for more information about the trial)

Research Study Number

Principle Investigator
Dr. Martin Gutierrez


Bristol-Myers Squibb

Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at

Apply Now